Publication | Open Access
Study Design: Human Leukocyte Antigen Class I Molecule A∗02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation
57
Citations
30
References
2022
Year
The STEADFAST study represents the next frontier in adoptive cell therapies. TX200-TR101 holds great potential to prevent immune-mediated graft rejection and induce immunologic tolerance after HLA-A<sup>∗</sup>02-mismatched renal transplantation.
| Year | Citations | |
|---|---|---|
Page 1
Page 1